Stockscreener 앱 받기
0.8457
9.36%
-0.0873
시간 외 거래:
.89
0.0443
+5.24%
Karyopharm Therapeutics Inc 주식(KPTI)의 최신 뉴스
Karyopharm Therapeutics Inc. Reports Q3 2024 Earnings - TipRanks
Karyopharm Therapeutics (KPTI) Q3 2024 Earnings Call Transcript - Yahoo Finance
Karyopharm Therapeutics: Q3 Earnings Snapshot - San Francisco Chronicle
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Q3 2024 Earnings: EPS Loss of - GuruFocus.com
Karyopharm Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Karyopharm Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress - PR Newswire
Karyopharm Therapeutics' SWOT analysis: oncology firm's stock faces pivotal year - Investing.com UK
Karyopharm Therapeutics Inc (KPTI) Q3 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
KPTIKaryopharm Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Karyopharm Therapeutics (KPTI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release - MSN
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Karyopharm Therapeutics (KPTI) to Release Quarterly Earnings on Tuesday - MarketBeat
Karyopharm Therapeutics' (KPTI) Buy Rating Reiterated at HC Wainwright - MarketBeat
Karyopharm updates SENTRY trial endpoints, eyes 2025 data - Investing.com India
Karyopharm updates SENTRY trial endpoints, eyes 2025 data By Investing.com - Investing.com Canada
Karyopharm gains after changes to late-stage trial - MSN
Karyopharm stock gains as late-stage trial changes (KPTI:NASDAQ) - Seeking Alpha
Karyopharm to Report Third Quarter 2024 Financial Results on November 5, 2024 - StockTitan
Karyopharm Announces Favorable Change in Co-Primary Endpoint for Pivotal Phase 3 SENTRY Trial in Myelofibrosis - StockTitan
Karyopharm to Host Investor Event with Leading Myelofibrosis KOLs and Provide a Favorable Study Design Update on October 31, 2024 - Investor Relations | Karyopharm Therapeutics
Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200 Day Moving AverageHere's What Happened - MarketBeat
Highbridge Capital Management's Strategic Acquisition of Karyopharm Therapeutics Shares - Yahoo Finance
Highbridge Capital Management's Strategic Acquisition of Karyoph - GuruFocus.com
Karyopharm Therapeutics (NASDAQ:KPTI) Shares Cross Above 50-Day Moving AverageShould You Sell? - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Holdings Lifted by AQR Capital Management LLC - MarketBeat
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Karyopharm Therapeutics Inc [KPTI] Records 200-Day SMA of $1.0212 - Knox Daily
Ratios in Focus: Analyzing Karyopharm Therapeutics Inc (KPTI)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
KPTI’s latest rating updates from top analysts. - Knox Daily
Karyopharm Therapeutics Inc (KPTI) is looking forward to a strong quarter - SETE News
Karyopharm Therapeutics Inc (KPTI) stock analysis: A simple moving average approach - US Post News
Cubist Systematic Strategies LLC Buys New Shares in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Marshall Wace LLP Decreases Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
Cubist Systematic Strategies LLC Takes Position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - MarketBeat
Karyopharm Therapeutics Inc [NASDAQ: KPTI] Sees Decrease in Stock Value - Knox Daily
Was Karyopharm Therapeutics Inc (KPTI)’s session last reading good? - US Post News
Monitoring Karyopharm Therapeutics Inc (KPTI) after recent insider movements - Knox Daily
Analyzing the Impact of Earnings Reports on Karyopharm Therapeutics Inc Inc. (KPTI) Price Performance - The InvestChronicle
Why Investors Shouldn't Be Surprised By Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Low P/S - Simply Wall St
Financial Snapshot: Analyzing Karyopharm Therapeutics Inc (KPTI)’s Key Ratio Metrics - The Dwinnex
A new trading data show Karyopharm Therapeutics Inc (KPTI) is showing positive returns. - SETE News
Karyopharm Therapeutics' SWOT analysis: pipeline potential drives stock outlook - Investing.com India
Karyopharm Therapeutics' SWOT analysis: pipeline potential drives stock outlook By Investing.com - Investing.com UK
SVP, General Counsel&Secretary Mano Michael sold 3,971 shares of Karyopharm Therapeutics Inc [KPTI] - Knox Daily
Karyopharm Therapeutics Inc (KPTI) Performance and Fundamentals Dashboard tells a completely different story - SETE News
The Globe and Mail - The Globe and Mail
A stock that deserves closer examination: Karyopharm Therapeutics Inc (KPTI) - US Post News
Metric Deep Dive: Understanding Karyopharm Therapeutics Inc (KPTI) Through its Ratios - The Dwinnex
KJTS Group shares climb to near six-week high after contract win - The Edge Malaysia
Market Movers to Watch: Black Diamond (Nasdaq: BDTX), Peraso Inc. (NASDAQ: PRSO), Kaival Brands (NASDAQ: KAVL) among others w/Key Announcements - Barchart
KEC International Shares Surge 3% on Securing Orders Worth Rs 1,003 Crore - EquityPandit
KEC International Boosts Market Presence with Rs 1,003 Crore New Contracts - PUNE.NEWS
KEC International surges 3% after bagging orders worth Rs 1,003 cr; details - Business Standard
India's KEC International rises on 10.03 bln rupee order wins - XM
KEC International shares surge 4% on new orders worth Rs 1,003 crore - Moneycontrol
Acadian Asset Management LLC Invests $167,000 in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) - Defense World
KEC International down 5% as CARE Ratings downgrades co's bank facilities - Business Standard
KEC International shares drop 4% after credit rating downgrade by CARE - Business Upturn
5:1 Stock Split Announced by This Multibagger Smallcap Company- Stock Hits 52-Week High Today, Gains Over 1,000 Per cent Returns in Just 1 Year! - Dalal Street Investment Journal
KHPT unveils ACE Market IPO prospectus to raise up to RM29 mil - The Edge Malaysia
Karyopharm faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia
Karyopharm faces Nasdaq delisting over share price woes - Investing.com India
2.02%
0.47%
자본화:
|
볼륨(24시간):